Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Cancer Immunotherapy Market Size Forecast: How Big Could The Market Get By 2030?
The cancer immunotherapy market size has seen rapid expansion over recent years. It is anticipated to expand from $124.09 billion in 2025 to $137.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.2%. The historical growth of this market can be linked to several factors, including major advancements in tumor immunology, a rise in global cancer incidence, the early efficacy of monoclonal antibodies, enhanced funding for oncology research and development, and the regulatory approvals granted for checkpoint inhibitors.
The cancer immunotherapy market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $210.39 billion in 2030, achieving a compound annual growth rate (CAGR) of 11.1%. This expansion during the forecast period can be attributed to factors such as the increasing adoption of CAR T-cell therapies, the extension into solid tumor indications, heightened investment in cancer vaccines, a growing demand for targeted combination therapies, and supportive reimbursement policies for immunotherapy. Significant trends expected in this period include the rapid embrace of immune checkpoint inhibitors, an expanding use of combination immunotherapy regimens, the proliferation of cell-based cancer therapies, an increasing focus on personalized immunotherapy, and a rising number of oncology clinical trials.
Get A Free Sample Report With In-Depth Market Insights:
Cancer Immunotherapy Market Growth Catalysts And Demand Drivers
The projected increase in cancer cases is anticipated to drive growth in the cancer immunotherapy market. Globally, several factors such as tobacco use, alcohol consumption, obesity, inactive lifestyles, and environmental elements are contributing to the rise in cancer diagnoses. This surge in cancer occurrences is projected to stimulate demand for cancer immunotherapies, given that patients are increasingly seeking medical treatments offering improved recovery rates and reduced discomfort. For example, in July 2024, Cancer Research UK, a UK-based cancer charity, published projections indicating that cancer incidence rates in the United Kingdom are forecast to rise for the majority of cancer types between 2023-2025 and 2038-2040. These increases are expected to range from less than 1% for breast cancer to 50% for eye cancer. Conversely, a limited number of cancers are predicted to decrease, with reductions from 2% for lung cancer to 27% for mesothelioma. Consequently, the expanding incidence of cancer is anticipated to elevate the demand for cancer immunotherapy throughout the forecast period.
Cancer Immunotherapy Market Segment Analysis And Revenue Potential
The cancer immunotherapy market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
3) By End User: Hospitals, Cancer Research Centers, Clinics
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists
4) By Vaccines: Therapeutic Cancer Vaccines
5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy
Cancer Immunotherapy Market Trends Shaping Long-Term Demand
Leading companies in the cancer immunotherapy market are concentrating on developing innovative solutions, such as PD-1 immunotherapies, to enhance the availability of advanced immune-based treatment options for patients suffering from hard-to-treat cancers. A PD-1 immunotherapy is a treatment designed to target immune checkpoints, stimulating antitumor immune activity by blocking interactions in the programmed death-1 pathway. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical firm specializing in oncology and biologics, launched HETRONIFLY (Serplulimab). This therapy is the world’s first programmed death-1 inhibitor approved for extensive-stage small cell lung cancer and operates via a dual mechanism targeting PD-L1 and PD-L2, with strong receptor internalization to boost immune engagement. Its demonstrated benefits in terms of survival and substantially reduced cost compared to existing immunotherapies emphasize its clinical value and widen patient access to advanced cancer treatment in India.
Cancer Immunotherapy Market Key Players Shaping Industry Direction
Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.
View The Full Cancer Immunotherapy Market Report:
Cancer Immunotherapy Market Geographic Distribution And Regional Opportunities
North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
